BR0313455A - modulação "antisense" da expressão de nav1.3 - Google Patents
modulação "antisense" da expressão de nav1.3Info
- Publication number
- BR0313455A BR0313455A BRPI0313455-5A BR0313455A BR0313455A BR 0313455 A BR0313455 A BR 0313455A BR 0313455 A BR0313455 A BR 0313455A BR 0313455 A BR0313455 A BR 0313455A
- Authority
- BR
- Brazil
- Prior art keywords
- antisense
- expression
- modulation
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
MODULAçãO ANTISENSE DA EXPRESSãO DE Nan1.3. São proporcionados compostos "antisense", composições e métodos para a modulação da expressão do canal de sódio Tipo lll Nav1.3. As composições compreendem compostos "antisense", particularmente oligonucleótidos "antisense", dirigidos a ácidos nucleicos codificadores de Nav1.3. São proporcionados métodos de utilização destes compostos para a modulação da expressão de Nan1.3 e para o tratamento de doenças associadas à expressão de Nav1.3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40341602P | 2002-08-14 | 2002-08-14 | |
PCT/US2003/025465 WO2004016754A2 (en) | 2002-08-14 | 2003-08-14 | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313455A true BR0313455A (pt) | 2007-07-31 |
Family
ID=31888234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313455-5A BR0313455A (pt) | 2002-08-14 | 2003-08-14 | modulação "antisense" da expressão de nav1.3 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1578927A2 (pt) |
JP (1) | JP2006507808A (pt) |
AU (1) | AU2003268096A1 (pt) |
BR (1) | BR0313455A (pt) |
CA (1) | CA2495398A1 (pt) |
MX (1) | MXPA05001836A (pt) |
WO (1) | WO2004016754A2 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005038013A1 (en) | 2003-10-07 | 2005-04-28 | Isis Pharmaceuticals, Inc. | Artisense oligonucleotides optimized for kidney targeting |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
GB0719367D0 (en) | 2007-10-03 | 2007-11-14 | Procarta Biosystems Ltd | Transcription factor decoys, compositions and methods |
JP2011502515A (ja) * | 2007-11-09 | 2011-01-27 | アイシス ファーマシューティカルズ インコーポレイティッド | 第9因子発現の調節 |
NZ585250A (en) * | 2007-11-09 | 2012-06-29 | Isis Pharmaceuticals Inc | Antisense modulation of factor 7 expression |
GB0906130D0 (en) * | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
US9068183B2 (en) * | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
GB201002413D0 (en) | 2010-02-12 | 2010-03-31 | Procarta Biosystems Ltd | Nucleic acid complexes |
GB201005545D0 (en) | 2010-04-01 | 2010-05-19 | Procarta Biosystems Ltd | Transcription factor decoys |
KR102008708B1 (ko) | 2010-06-23 | 2019-08-08 | 큐알엔에이, 인크. | 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료 |
ES2688831T3 (es) | 2012-06-25 | 2018-11-07 | Ionis Pharmaceuticals, Inc. | Modulación de la expresión de UBE3A-ATS |
WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
ES2852998T3 (es) | 2015-11-12 | 2021-09-14 | Hoffmann La Roche | Oligonucleótidos para inducir la expresión de UBE3A paterno |
TWI809004B (zh) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
CN113329739A (zh) * | 2018-08-20 | 2021-08-31 | 罗贡股份有限公司 | 用于治疗scn1a脑病的靶向scn2a的反义寡核苷酸 |
AU2020253821A1 (en) | 2019-03-29 | 2021-10-28 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating UBE3A-ATS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
US6124133A (en) * | 1999-10-15 | 2000-09-26 | Isis Pharmaceuticals Inc. | Antisense inhibition of fra-1 expression |
EP1425403B1 (en) * | 2001-09-14 | 2008-12-31 | Oxford Biomedica (UK) Limited | Lentiviral vectors for the treatment of pain |
-
2003
- 2003-08-14 WO PCT/US2003/025465 patent/WO2004016754A2/en not_active Application Discontinuation
- 2003-08-14 MX MXPA05001836A patent/MXPA05001836A/es not_active Application Discontinuation
- 2003-08-14 AU AU2003268096A patent/AU2003268096A1/en not_active Abandoned
- 2003-08-14 EP EP03749047A patent/EP1578927A2/en not_active Withdrawn
- 2003-08-14 BR BRPI0313455-5A patent/BR0313455A/pt not_active Application Discontinuation
- 2003-08-14 CA CA002495398A patent/CA2495398A1/en not_active Abandoned
- 2003-08-14 JP JP2004529403A patent/JP2006507808A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2004016754A2 (en) | 2004-02-26 |
CA2495398A1 (en) | 2004-02-26 |
JP2006507808A (ja) | 2006-03-09 |
AU2003268096A8 (en) | 2004-03-03 |
EP1578927A2 (en) | 2005-09-28 |
AU2003268096A1 (en) | 2004-03-03 |
WO2004016754A3 (en) | 2005-11-10 |
MXPA05001836A (es) | 2005-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313455A (pt) | modulação "antisense" da expressão de nav1.3 | |
DK1250455T3 (da) | Antisense-inhibering af PTP1B-ekspression | |
DK1117672T3 (da) | Antisense-modulation af survivin-ekpression | |
DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
WO2003008543A3 (en) | Antisense modulation of bcl2-associated x protein expression | |
WO2003066805A3 (en) | Antisense modulation of complement component c3 expression | |
WO2001029175A3 (en) | Antisense modulation of fra-1 expression | |
WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
WO2003104397A3 (en) | ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION | |
WO2001083513A3 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
EP1144690A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF A CELLULAR APOPTOSIS-2 INHIBITOR | |
AU2606000A (en) | Antisense modulation of x-linked inhibitor of apoptosis expression | |
BR0313550A (pt) | modulação "antisense" da expressão de sintetase 1 de acil-coa | |
WO2003099224A3 (en) | Antisense moodulation of kinesin-like 1 expression | |
EP1390388A4 (en) | ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 1 EXPRESSION | |
WO2004003201A3 (en) | Antisense modulation of lrh1 expression | |
EP1441740A4 (en) | ANTI-SENSE MODULATION OF THE EXPRESSION OF MATRIX METALLOPROTEINASE 1 | |
WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
WO2003105754A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION | |
WO2002041836A3 (en) | Antisense modulation of src-1 expression | |
WO2004011623A3 (en) | Antisense modulation of ptpra expression | |
WO2004014299A3 (en) | Antisense modulation of resistin expression | |
WO2002097108A3 (en) | Antisense modulation of dual specific phosphatase 5 expression | |
WO2002040637A3 (en) | Antisense modulation of pi3k p85 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |